About Odonate Therapeutics (NASDAQ:ODT)
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$7.29 per share
Price / Book3.19
Return on EquityN/A
Return on AssetsN/A
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics (NASDAQ:ODT) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.14. View Odonate Therapeutics' Earnings History.
Where is Odonate Therapeutics' stock going? Where will Odonate Therapeutics' stock price be in 2018?
3 brokerages have issued 12-month target prices for Odonate Therapeutics' shares. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next year. View Analyst Ratings for Odonate Therapeutics.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include Pacira Pharmaceuticals (PCRX), PTC Therapeutics (PTCT), Arena Pharmaceuticals (ARNA), Cellectis (CLLS), Assembly Biosciences (ASMB), ARMO Biosciences (ARMO), Acorda Therapeutics (ACOR), Genomic Health (GHDX), Wave Life Sciences (WVE), G1 Therapeutics (GTHX), Myovant Sciences (MYOV), Revance Therapeutics (RVNC), TherapeuticsMD (TXMD), Bavarian Nordic (BVNRY), DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Athenex (ATNX) and Intellia Therapeutics (NTLA).
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Kevin C. Tang, Chairman of the Board, Chief Executive Officer (Age 50)
- Jeff L. Vacirca M.D., Vice Chairman of the Board (Age 48)
- John G. Lemkey, Chief Financial Officer (Age 37)
- Robert D. Millham, Chief Operating Officer (Age 55)
- Stewart M. Kroll, Senior Vice President - Biometrics (Age 59)
- Thomas Wei, Senior Vice President - Research and Strategy (Age 41)
- Natasha M. Bartasch-Price, Vice President - Program Management (Age 38)
- Nicole H. Gollaher J.D., Vice President - Legal Affairs (Age 48)
- Valerie L. Legagneur, Vice President - Clinical Operations (Age 43)
- Steven S. Pfeiffer Ph.D., Vice President - Technical Operations (Age 42)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.
When does Odonate Therapeutics' lock-up period expire?
Odonate Therapeutics' lock-up period expires on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its IPO on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. After the expiration of Odonate Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Has Odonate Therapeutics been receiving favorable news coverage?
News stories about ODT stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Odonate Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news coverage about the company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (5.87%), Sabby Management LLC (3.07%), Redmile Group LLC (2.22%), Rock Springs Capital Management LP (1.52%), Allianz Asset Management GmbH (0.91%) and Perceptive Advisors LLC (0.56%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which institutional investors are buying Odonate Therapeutics stock?
ODT stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Sabby Management LLC, Redmile Group LLC, Rock Springs Capital Management LP, Allianz Asset Management GmbH, Perceptive Advisors LLC, Monashee Investment Management LLC and Victory Capital Management Inc.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $23.25.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $635.45 million. Odonate Therapeutics employs 60 workers across the globe.
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (ODT)MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Odonate Therapeutics (NASDAQ:ODT) Earnings History and Estimates Chart
Odonate Therapeutics (NASDAQ ODT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Odonate Therapeutics (NASDAQ:ODT) Earnings Estimates
2018 EPS Consensus Estimate: ($4.30)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Odonate Therapeutics (NASDAQ:ODT)
No dividend announcements for this company have been tracked by MarketBeat.com
Odonate Therapeutics (NASDAQ ODT) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 78.92%
Odonate Therapeutics (NASDAQ ODT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/1/2018||Kevin C Tang||CEO||Buy||14,050||$27.42||$385,251.00|| |
|2/27/2018||Kevin C Tang||CEO||Buy||28,612||$27.42||$784,541.04|| |
|2/22/2018||Kevin C Tang||CEO||Buy||39,083||$27.17||$1,061,885.11|| |
|2/16/2018||Kevin C Tang||CEO||Buy||128,255||$22.47||$2,881,889.85|| |
|12/12/2017||Jeff L Vacirca||Director||Buy||1,000||$23.30||$23,300.00|| |
|12/7/2017||Kevin C Tang||CEO||Buy||1,291,666||$24.00||$30,999,984.00|| |
|12/6/2017||Boxer Capital, Llc||Director||Buy||416,666||$24.00||$9,999,984.00|| |
Odonate Therapeutics (NASDAQ ODT) News Headlines
|Zacks: Brokerages Set $40.00 Target Price for Odonate Therapeutics Inc (ODT)|
www.americanbankingnews.com - March 11 at 5:28 PM
|Zacks Investment Research Downgrades Odonate Therapeutics (ODT) to Sell|
www.americanbankingnews.com - March 11 at 1:48 PM
| Odonate Therapeutics Inc (ODT) Given $40.00 Consensus Price Target by Brokerages|
www.americanbankingnews.com - March 8 at 5:25 PM
| Analysts Anticipate Odonate Therapeutics Inc (ODT) to Post -$0.86 EPS|
www.americanbankingnews.com - March 7 at 3:18 PM
|Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $385,251 of Shares|
finance.yahoo.com - March 3 at 9:22 AM
|Odonate Therapeutics Inc (ODT) CEO Buys $385,251.00 in Stock|
www.americanbankingnews.com - March 2 at 6:40 PM
|Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $784,541 of Shares|
finance.yahoo.com - February 28 at 9:21 AM
|Kevin C. Tang Purchases 28,612 Shares of Odonate Therapeutics Inc (ODT) Stock|
www.americanbankingnews.com - February 27 at 6:32 PM
|Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.1 million of Shares|
finance.yahoo.com - February 23 at 9:20 AM
|Kevin C. Tang Purchases 39,083 Shares of Odonate Therapeutics Inc (ODT) Stock|
www.americanbankingnews.com - February 22 at 9:20 PM
|Odonate Therapeutics Inc (ODT) CEO Kevin C. Tang Buys 128,255 Shares|
www.americanbankingnews.com - February 16 at 9:10 PM
|Jefferies Group Brokers Cut Earnings Estimates for Odonate Therapeutics Inc (ODT)|
www.americanbankingnews.com - February 16 at 7:56 AM
|Odonate Therapeutics (ODT) Issues Quarterly Earnings Results|
www.americanbankingnews.com - February 15 at 11:52 PM
|Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017|
finance.yahoo.com - February 14 at 9:12 AM
|Odonate Therapeutics LLC's (ODT) Quiet Period Set To End on January 16th|
www.americanbankingnews.com - January 9 at 1:22 AM
|Odonate Therapeutics LLC to Post FY2017 Earnings of ($1.83) Per Share, Jefferies Group Forecasts (ODT)|
www.americanbankingnews.com - January 4 at 6:34 AM
|Odonate Therapeutics (ODT) Now Covered by Goldman Sachs Group|
www.americanbankingnews.com - January 2 at 10:18 AM
|Odonate Therapeutics (ODT) Coverage Initiated at Cowen|
www.americanbankingnews.com - January 2 at 8:04 AM
|Jeff L. Vacirca Purchases 1,000 Shares of Odonate Therapeutics LLC (ODT) Stock|
www.americanbankingnews.com - December 14 at 9:38 PM
|Odonate Therapeutics LLC (ODT) Director Boxer Capital, Llc Purchases 416,666 Shares|
www.americanbankingnews.com - December 8 at 8:28 PM
|Insider Buying: Odonate Therapeutics LLC (ODT) CEO Acquires 1,291,666 Shares of Stock|
www.americanbankingnews.com - December 8 at 5:30 PM
Odonate Therapeutics (NASDAQ:ODT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Odonate Therapeutics (NASDAQ ODT) Stock Chart for Sunday, March, 18, 2018